drugset / Trial / NCT02479698

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

NCT02479698 ↗

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.

Timeline

Start
2015-07-23
Primary completion
2027-07-31
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic BK-specific Cytotoxic T-lymphocytes Cell therapy 200000 cells/kg Intravenous